What's Behind Ionis Pharmaceuticals' Q3 Earnings Disappointment
It's been a rough year so far for Ionis Pharmaceuticals (NASDAQ: IONS). Its shares have plunged more than 20%. None of the positive developments achieved by the biotech have been enough to get investors excited.
Ionis announced its third-quarter results before the market opened on Wednesday. And investors probably still aren't too excited. Here are the highlights from the company's Q3 update.
Image source: Getty Images.
Source Fool.com
